Tel Aviv, Israel: Children with refractory epilepsy respond favorably to long-term treatment with plant-derived CBD extracts, according to data published in Pediatric Neurology.
Israeli researchers assessed the safety and efficacy of artisanal CBD-rich extracts in a cohort of adolescents with treatment-resistant forms of epilepsy. Among patients administered extracts for a period of at least one year, 51 percent experienced a significant decline in seizure frequency. Patients reported only nominal side-effects associated with CBD treatment.
Authors concluded, “Artisanal cannabidiol-enriched cannabis may be an effective and safe long-term treatment for refractory epilepsy.”
In 2018, the US Food and Drug Administration granted market approval to Epidiolex, a prescription medicine containing a standardized formulation of plant-derived cannabidiol for the treatment of two rare forms of severe epilepsy: Lennox-Gastaut syndrome and Dravet syndrome. Shortly after approval, the US Drug Enforcement Administration reclassified Epidiolex to Schedule V of the US Controlled Substances Act — the lowest restriction classification available under federal law.
Full text of the study, “The long-term effectiveness and safety of cannabidiol-enriched oil in children with drug-resistant epilepsy,” appears in Pediatric Neurology. Additional information on cannabis and epilepsy is available from NORML.
Source: NORML – make a donation